ImmunityBio, Inc. (IBRX) is a San Diego-based clinical-stage immunotherapy company whose lead product, Anktiva (nogapendekin alfa inbakicept), is approved to treat certain forms of bladder cancer. The central $14 target reflects four current analyst price targets gathered from S&P Global and Yahoo Finance data: BTIG at $12 (maintained October 30, 2026), Jefferies at $14 (raised from $12 on October 14, 2026), H.C. Wainwright at $15 (reiterated October 15, 2026), and Piper Sandler at $16 (raised from $12 on October 14, 2026). The arithmetic mean of these four targets is $14.25, which rounds to the $14 central target used here, with a low-to-high range of $12 to $16.
All four firms carry Buy-equivalent ratings, and the broader consensus is characterized as "Strong Buy." The recent target increases from Jefferies and Piper Sandler followed the FDA's decision to expand Anktiva's approved indication to include BCG-unresponsive non-muscle-invasive bladder cancer with papillary-only tumors. It is important to note that most of these targets were set before the company's third-quarter earnings report, which could prompt downward revisions.
At a recent close of $8.64, IBRX trades near the middle of a 52-week range of $1.95 to $12.43, with a market capitalization of roughly $9.2 billion. Reaching $14 would require an advance of about 62% from that level, a very large move. The stock has delivered an extraordinary run, gaining more than 300% over the trailing year, but it pulled back sharply after third-quarter results showed revenue of $48.84 million versus a consensus near $59.2 million and a wider-than-expected adjusted loss.
The path toward the target depends heavily on whether Anktiva's commercial ramp resumes its prior trajectory. Revenue has grown rapidly, with Q2 2026 revenue of $51.2 million up about 94% year over year, and management has pointed to an eighth consecutive quarter of sequential product growth. Continued label expansion, international launches, and progress in the Phase 3 QUILT-2.005 trial could all support a higher valuation, but the stock remains unprofitable and trades on forward revenue rather than earnings.
Several verified developments underpin the bullish case. In October 2026 the FDA broadened Anktiva's label to include papillary-only tumors, meaningfully expanding the addressable patient population. The company also reported that Anktiva combined with BCG met the primary endpoint of the QUILT-2.005 Phase 3 trial in BCG-naïve patients, with plans to seek approval by year-end. Internationally, Anktiva has received authorizations across more than 30 countries, including Saudi Arabia, the United Arab Emirates, and Israel, and an Irish subsidiary supports a planned European launch. A PDUFA decision on a further label expansion is expected in early January 2027.
The principal obstacles are financial. Third-quarter revenue missed estimates for the first time in six quarters, and management included a going-concern disclosure citing substantial doubt about its ability to continue without additional financing or related-party support. Total liabilities were reported near $1.75 billion, with roughly $334 million in cash, equivalents, and marketable securities at quarter-end. The company has also used an at-the-market (ATM) offering program, which can dilute shareholders. Insider selling under pre-arranged plans and the wide gap between a $9 billion-plus market value and limited current revenue add further uncertainty. A securities class-action lawsuit has also been filed, a common but notable overhang for a stock that has fallen sharply.
Technically, IBRX sits just above its 200-day moving average near $7.96 but below its 50-day moving average near $8.74, a mixed picture following the post-earnings sell-off. The 52-week high of $12.43 stands between the current price and the $14 target and represents a meaningful resistance area. Below, the recent pre-market low near $7.37 and the round-number $7 zone mark near-term support. A decisive move back above the 50-day average could signal renewed momentum, while a break below the 200-day average would suggest the pullback has further to run.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms may differ. Key upcoming items include the January 2027 FDA decision on further label expansion, the company's fourth-quarter earnings and revenue trajectory, any analyst target revisions following the Q3 miss, and announcements on financing, international launches, and the BCG-naïve regulatory filing. Signs of renewed Anktiva revenue acceleration and clarity on the company's capital position are the most important variables.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover new opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening. For those tracking volatile names like IBRX, it can serve as a supplemental signal to traditional research.
The $14 central target represents the average of four current analyst price targets, and it implies a roughly 62% gain from a recent price of $8.64. The bullish case rests on genuine momentum in Anktiva's label expansion, clinical data, and international rollout. The bearish case rests on a revenue miss, a going-concern disclosure, and financing risk. Analyst views are uniformly positive but clustered between $12 and $16, and the targets largely predate the disappointing third-quarter report. Whether IBRX reaches $14 will depend on whether commercial execution and regulatory milestones can overcome the company's near-term balance-sheet concerns; no outcome is guaranteed.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, IBRX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if IBRX jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To IBRX | 1D Price Change % | ||
|---|---|---|---|---|
| IBRX | 100% | -0.66% | ||
| AXON - IBRX | 48% Loosely correlated | -2.85% | ||
| ARRY - IBRX | 41% Loosely correlated | -3.51% | ||
| QTTB - IBRX | 39% Loosely correlated | -4.82% | ||
| NTLA - IBRX | 38% Loosely correlated | +1.65% | ||
| FTH - IBRX | 37% Loosely correlated | -7.48% | ||
More | ||||